Clinical trials: Fludzoparib" and Anti-angiogenic
Fludzoparib" and Anti-angiogenic, HRD-positive/HER2-negative Advanced Breast Cancer
Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer
This study develops a new therapeutic approach for HER2-negative advanced breast cancer patients without precise treatment targets.
- Trial name
- NCT06255392
- Testing
- Fluzoparib, Apatinib Mesylate, Capecitabine tablets
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University